Morgan Stanley’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-275,990
| Closed | -$2.65M | – | 8328 |
|
|
2024
Q4 | $2.65M | Sell |
275,990
-263,020
| -49% | -$1.37M | ﹤0.01% | 4502 |
|
|
2024
Q3 | $1.54M | Buy |
539,010
+175,729
| +48% | +$544K | ﹤0.01% | 4796 |
|
|
2024
Q2 | $1.06M | Sell |
363,281
-105,295
| -22% | -$288K | ﹤0.01% | 4924 |
|
|
2024
Q1 | $1.49M | Sell |
468,576
-214,702
| -31% | -$716K | ﹤0.01% | 4738 |
|
|
2023
Q4 | $2.3M | Buy |
683,278
+404,120
| +145% | +$1.04M | ﹤0.01% | 4850 |
|
|
2023
Q3 | $664K | Sell |
279,158
-276,758
| -50% | -$580K | ﹤0.01% | 5025 |
|
|
2023
Q2 | $978K | Buy |
555,916
+74,090
| +15% | +$189K | ﹤0.01% | 4846 |
|
|
2023
Q1 | $1.48M | Buy |
481,826
+375,739
| +354% | +$2.25M | ﹤0.01% | 4628 |
|
|
2022
Q4 | $562K | Buy |
106,087
+36,628
| +53% | +$167K | ﹤0.01% | 5182 |
|
|
2022
Q3 | $245K | Sell |
69,459
-3,114
| -4% | -$10.3K | ﹤0.01% | 5634 |
|
|
2022
Q2 | $188K | Buy |
72,573
+19,908
| +38% | +$55.4K | ﹤0.01% | 5934 |
|
|
2022
Q1 | $236K | Buy |
52,665
+7,857
| +18% | +$35.4K | ﹤0.01% | 5827 |
|
|
2021
Q4 | $306K | Buy |
44,808
+9,853
| +28% | +$67.1K | ﹤0.01% | 5831 |
|
|
2021
Q3 | $254K | Buy |
34,955
+13,893
| +66% | +$119K | ﹤0.01% | 5873 |
|
|
2021
Q2 | $212K | Buy |
21,062
+20,496
| +3,621% | +$184K | ﹤0.01% | 5986 |
|
|
2021
Q1 | $6K | Sell |
566
-9,358
| -94% | -$91.8K | ﹤0.01% | 7074 |
|
|
2020
Q4 | $109K | Buy |
9,924
+7,850
| +378% | +$82.8K | ﹤0.01% | 5874 |
|
|
2020
Q3 | $18K | Buy |
+2,074
| New | +$23.6K | ﹤0.01% | 6103 |
|
Other funds holding PSTX
Morgan Stanley's PSTX Position: Q1 2025 in Review
Morgan Stanley sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 275,990 shares — an estimated $2.65M sold.
Morgan Stanley first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $2.65M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Morgan Stanley reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Morgan Stanley sold 275,990 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $2.65M.
- Morgan Stanley first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Morgan Stanley's Poseida Therapeutics, Inc. Common Stock position peaked at $2.65M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.